DLQI – Published Abstracts

Subsequent abstracts too numerous to list here

1997

1.        Williamson D, Gonzalez M, Finlay AY.  Quality of life in patients with hair loss. British Journal of Dermatology 1997; 137 (Suppl 50): 47.

1998

2.        Finlay AY, Coles EC, Lewis-Jones MS, Blackford S, Holt PJA, Howard A, Knight AG, Lanigan SW, Logan RA, Long CC, Marks R, Motley RJ, Roberts DLL, Statham BN, Wilkins J.  Quality of life improves after seeing a dermatologist. British Journal of Dermatology 1998; 139 (Suppl 51): 15.

3.        Harlow D, Poyner T, Finlay AY, Dykes PJ. High impairment of quality of life of adults with skin diseases in primary care.  British Journal of Dermatology1998; 139 (Suppl 51): 15.

4.        Poon E, Greaves MW, Kobza-Black A.  Extent of disability in different urticarial disorders.  British  Journal of Dermatology 1998; 139 (Suppl 51): 15.

5.        Ruta D, Allen S, Herd R, Tidman M. The patient generated index: a new approach to quality of life measurement in psoriasis. Quality of Life Research1998; 7: 657.

1999

6.        Ayyalaraju RS, Finlay AY, Kirsner RS, Trent JT, Kerdel FA.  Dermatology Inpatient Services: A UK/USA Comparative Study.  British Journal of Dermatology 1999; 141 (Suppl 55): 79-80.

7.        Kochergin NG, Ivandv OL, Burova EP.  Quality of Life and Long Term Cyclosporine, a Treatment in Psoriasis.  Journal of the European Academy of Dermatology and Venereology 1999; 12 (Suppl 2): S333.

8.        Mufleh L, Gonzalez M, Judodihardjo H, Finlay AY.  Compliance is high in patients taking oral Isotretinoin for acne.  British Journal of Dermatology 1999; 141 (Suppl 55): 87.

9.        Zaghloul S, Gonzalez M, Judodihardjo H, Finlay AY.  In psoriasis, the greater the disability, the poorer the topical treatment compliance.  British Journal of Dermatology 1999; 141 (Suppl 55): 48.

2000

10.      Al-Awadi R, Dykes P J, Gonzalez M, Finlay A Y  Life activity impairment by skin disease.  J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1):  54.

11.      Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kerdel F A, Kirsner R S. Dermatology in-patients services:  A UK/USA comparative study.  J Invest Dermatol 2000; 114: 886.

12.      Bissonnette R, Papp K A, Garovoy M, Walicke P, Watrous W.  Hu 1124 improves dermatological-specific quality of life in subjects with moderate-severe psoriasis.   J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1):  255.

13.      Helbing I, Muston HL, Ferguson JE.  Audit of admissions to dermatology beds in the north-west.  British Journal of Dermatology 2000; 143 (Suppl 57): 42.

14.      Hutchings CV, Shum KW, Gawkrodger DJG.  Occupational contact dermatitis has an appreciable impact on quality of life.  British Journal of Dermatology2000; 143 (Suppl 57): 27.

15.      Lanigan SW, Kwan CK, Dykes PJ, Gonzalez MG.  Quality of life studies in hirsute women receiving ruby laser treatment.  British Journal of Dermatology2000; 143 (Suppl 57): 50.

16.      Mork C, Wahl A.  Supervised climatotherapy improves quality of life and disease severity among patients with psoriasis.  Quality of Life Research 2000; 9: Poster 43.

17.      Rzany B J, Partscht K, Kippes W, Ettrich A, Baima B et al.  Quality of life in patients with Bullous pemphigoid.  J Invest Dermatol 2000; 114: 887.

2001

18.      Amir M, Vardy D, Narkiss T et al.  Heliotherapy at the Dead Sea improves quality of life in psoriatic patients: a prospective study.  Qual Life Research 2001; 10, 3: 236.

19.      Christophers E, Bourcier M, Griffiths C, et al.  Study design and demographics of a randomised, double-blind, placebo-controlled phase 3 dose-comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis.  JEADV 2001; 15 (Suppl 2): 249.

20.      Kochergin, N G, Burova E P.  Life quality assessment in psoriasis and atopic dermatitis. JEADV 2001; 15 (Suppl 2): 186.

21.      Lvov AN, Ivanov OL, et al.  Psychoneurological parameters and quality of life in patients with severe forms of atopic dermatitis. JEADV 2001; 15 (Suppl 2): 276.

22.     Ongenae K, De Schepper S, van Geel N et al.  Impact of vitiligo on the quality of life in Belgium. JEADV 2001; 15 (Suppl 2): 232.

23.     Thomas K, Williams A, Avery A et al.  Topical steroids in mild to moderate eczema – short burts of strong preparations or continuous use of minor ones?  J Invest Dermatol 2001; 17: 758.

24.     Thomson K F, Pollock B, Sommer S, Wilkinson S M.  The effect of patch testing on quality of life. Br J Dermatol 2001; 145 (Suppl 59): 19.

25.      Zaghloul S S, Cunliffe W J, Goodfield M J D.  Compliance in psoriasis is highly correlated with psychological well-being. Br J Dermatol 2001; 145 (Suppl 59): 41.

2002

26.      Ammad S, Edwards C, Gonzalez M, Mills CM.  The effect of blue light phototherapy on mild to moderate acne.  Br J Dermatol 2002; 147 (Suppl 62): 95.

27.      Campanati A, Guzzo T et al.  How botulinum A toxin modifies life quality of patients suffering from focal severe hyperhidrosis.  Ann Dermatol Venereol2002; 129: 1S695.

28.      Diba VC, Loo WJ, Chawla M, Finlay AY.  Dermatology Life Quality Index (DLQI) validation of an illustrated version. Ann Dermatol Venereol 2002; 129: 1S254-255.

29.      Ertam I.  Acne and quality of life: Is there a correlation between them in university students. Ann Dermatol Venereol 2002; 129: 1S374.

30.      Etemesi BA.  Quality of life in Tanzanian adults with chronic skin diseaseAnn Dermatol Venereol 2002; 129: 1S253.

31.      Gottlieb AB, Lowe NJ, Matheson RT, Lebsack ME.  Efficacy of etanercept in patients with psoriasis. Ann Dermatol Venereol 2002; 129: 1S280.

32.      Griffiths C E M, Humbert P, Koo J, Ortonne J P, Christophers E.  Relationship between clinical response and quality of life in psoriasis patients treated with alefacept. JEADV 2002; 16 (Suppl 1): 292.

33.      Griffiths C, Langley R et al.  Alefacept improves psoriasis and quality of life: Results of an international trial. Ann Dermatol Venereol 2002; 129: 1S280.

34.      Khilji FA, Gonzalez M, Finlay AY.  Clinical meaning of change in Dermatology Life Quality Index scores.  Br J Dermatol 2002; 147 (Suppl 62): 50.

35.      Kochergin N G, Samgin M A, Monakhow S A.  Acne, adapalene and quality of life.  JEADV 2002; 16 (Suppl 1):  116.

36.      Koo J, Menter A, Lebwohl M, Kozma C, Slaton T, Wojcik A Kowlaski J.  The relationship between quality of life and disease severity:  results from a large cohort of mild, moderate and severe psoriasis patients.  Br J Dermatol 2002; 147: 1070-1071.

37.      Lowe N, Lebsack M Wande L.  Psoriasis patients show improved quality of life when treated with Etanercept.  Ann Dermatol Venereol 2002; 129: 1S762.

38.      Meurer M, Folster-Holst R, Brautigam M.  Pimecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term management of atopic dermatitis in adults. Ann Dermatol Venereol 2002; 129: 1S47.

39.      Nicolaou M, Swan M C, Paes T.  Endoscopic transthoracic sympathectomy:  the effect on the quality of life of patients with facial, palmar and axillary hyperhidrosis and facial blushing. JEADV 2002; 16 (Suppl 1): 298.

40.      Nicolaou M, Swan MC, Paes T.  Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhidrosis.  Br J Dermatol 2002; 147 (Suppl 62): 59.

41.      Papp K, Ellis C et al  Alefacept improves psoriasis and quality of life:  Results of a multiple-course trial. Ann Dermatol Venereol 2002; 129: 1S764.

42.      Sivayathorn A.  Quality of life assessment in psoriasis.  Ann Dermatol Venereol2002; 129: 1S12.

43.      Urbanowski S, Kosmowski.  Quality of life, psychological condition, depression and alexithymia in patients with psoriasis vulgaris. Ann Dermatol Venereol2002; 129: 1S798.

44.      Zaghloul SS, Cunliffe WJ, Goodfield MJD.  Compliance in acne is highly correlated to psychological well-being and self presentation.  Br J Dermatol 2002; 147 (Suppl62): 43.

45.      Zaghloul SS, Goodfield MJD.  Compliance in psoriasis: patients’ self-reporting and factors affecting medication adherence.  Br J Dermatol 2002; 147 (Suppl 62): 43-44.

46.      Zollner TM, Paeslack I, Kaufmann R, Boehncke W H.  Effectiveness and quality of life in patients with disfigurating skin disease applying decorative cosmetics. Ann Dermatol Venereol 2002; 129: 1S44.

2003

47.      Berger K, Kugland B, Khlken B, Augustin M.  Cost of chronic plaque psoriasis in Germany:  an analysis from the patients and payer perspectives.  JEADV2003;  17 (Suppl 1): 36.

48.      Calikoglu E, Oztas P, Cetin P.  The evaluation of psychiatric tests in seborrhoeic dermatitis patients.  JEADV  2003; 17 (Suppl 3): 159.

49.      Callis K P, Carlin C S, Krueger C G.  Correlation of National Psoriasis Foundation score components with quality of life measures in psoriasis.   J Invest Dermatol 2003; 121(1): 0357.

50.      Carey W, Gulliver W P.  Efalizumab therapy improves and sustains health-related quality of life in patients with moderate to severe plaque psoriasis. JEADV  2003; 17 (Suppl 3) 371.

51.      Caro I, Leonardi C, Gottlieb A B, Zitnik R J.  Efficacy and safety of ENBREL® (Etanercept) in patients with psoriasis:  results of a 24-week US phase III study.    JEADV  2003; 17 (Suppl 3): 140.

52.      Caro I, Woolley J M, Zitnik R J.  Effects of etanercept therapy on health-related quality of life of subjects with moderate to severe psoriasis.  JEADV  2003; 17 (Suppl 3): 140.

53.      Chaidemenos C, Avgoustinaki N, Karakatsanis,G, Chatzistylianos,M, Papakonstantinou M, Mourellou O.  Effect of intermittent and continuous cyclosporin therapy on the clinical and quality of life parameters of psoriasis. JEADV  2003; 17 (Suppl 3): 381.

54.      Christopher E, Vanishnaw AK.  A broad spectrum of patients with psoriasis benefit from alefacept therapy.  JEADV  2003; 17 (Suppl 3): 138.

55.      Dierckxsen L, Ongenae K, van Geel N, Naeyaert J.  Vitiligo:  profile of a Belgian cohort.  JEADV  2003; 17 (Suppl 3) 359.

56.      Dierckxsen L, Ongenae K, van Geel N, Naeyaert J.  Vitiligo and quality of life:  impact of complexion corrector.  JEADV  2003; 17 (Suppl 3): 358.

57.      Etemesi B A.  Impact of chronic skin disease on the quality of life of Tanzanian adults. Br J Dermatol 2003; 149 (Suppl l 64): 31-32.

58.      Feldman S R, McMichael A, Balkrishnan R, Rapp S R, Crambes O, Abella M L, Bouloc A.  The effect of corrective cosmetics on quality of life of patients with facial disfigurements.  JEADV  2003; 17 (Suppl 3) 202.

59.      Finlay A Y, Myon E, Taieb C.  Immoderate exposure to the sun:  short-term impact on quality of life. JEADV 2003;  17 (Suppl 1):62.

60.      Finlay A Y.  Quality of life in dermatology – introduction to workshop.  JEADV 2003; 17 (Suppl 3): 58.

61.      Finlay A Y.  What do quality of life scores really mean?  JEADV  2003; 17 (Suppl 3): 58.

62.      Fleckman P, Hamill G, Weinstock M A.  The National Registry for Ichthyosis and Related disorders – health related quality of life and patient reported outcomes.  J Invest Dermatol 2003; 121(1): 0420.

63.      Gollnick H, Cunliffe W.  Report from a Global Alliance to Improve Outcomes in Acne.  JAAD 2003; 49: S32.

64.      Holloway V, Feldman S.  Corrective cosmetics improve the quality of life in patients with disfiguring disease.  JEADV  2003; 17 (Suppl 3): 427.

65.      Holm E A, Jemec G B E.  Why is assessment of health-related quality of life so important?  JEADV  2003; 17 (Suppl 3): 304.

66.      Holme S A, Edwards C, Hughes M T, Stone N M.  Dermatology quality of life during contact dermatitis patch testing investigations.  Br J Dermatol 2003; 148: 847.

67.      Hongbo Y, Harrison M A, Salek M S, Finlay A Y.  Assessing the meaningfulness of Dermatology Life Quality Index (DLQI) scores.   JEADV  2003; 17 (Suppl 3): 113.

68.      Hongbo Y, Harrison M A, Salek S S, Finlay A Y.  What do the Dermatology Life Quality Index (DLQI) scores really mean in terms of patients’ over all quality of life?  Quality of Life Research 2003; 12: 778.

69.      Humbert Ph, Bassas-Bresca S, van der Valk P, Merot F, Ermosilla S V, Boyer J F, Mengeaud J V.  Interest of an emollient combination of two hygiene products and a cream containing Oat Rhealba ® extract in atopic dermatitis. JEADV2003;  17 (Suppl 1): 50.

70.      Humbert Ph, Basses-Bresca S, van der Valk P, Mengeaud V, Ermosilla V, Boyer F, Merot F.  Interest of an emollient combination of two hygiene products and a cream containing Oak Rhealba ® extract in atopic dermatitis.  JEADV  200317 (Suppl 3): 174.

71.      Kirkup M E, Spicer J K, Rumsey N J, Kennedy C T C.  Quality of life in older adults with skin disorders. Br J Dermatol 2003; 149 (Suppl 64): 35.

72.      Kochergin N G, Yutanova N S.  Mometasone furoate 0.1% with salicylic acid
5% ointment in psoriasis and atopic dermatitis.  
JEADV  2003; 17 (Suppl 3): 350.

73.      Langley R.  An improvement of 50% or more in psoriasis area severity index (PASI) represents substantial improvement for patients treated with alefacept. JEADV  2003; 17 (Suppl 3): 139.

74.      Lewis V, Statham B, Chowdhury M.  How does the diagnosis of latex allergy affect people’s lives?    JEADV  2003; 17 (Suppl 3): 124.

75.      Lowe N, Yamauchi P, Zitnik R.  Efficacy and safety of Enbrel® (etanercept) in patients with psoriasis:  results of a phase III study. Br J Dermatol 2003; 149
(Suppl 64): 20.

76.      McPherson T, Penzer.  A comparison of quality of life and disease severity in 54 patients with lymphoedema in Guyana. Br J Dermatol 2003; 149 (Suppl 64): 34.

77.      Ouellet J P, Toth D, Gratton D.  Efalizumab provides rapid onset of clinical benefit in patients with moderate to severe plaque psoriasis.  JEADV  2003; 17 (Suppl 3) 371.

78.      Öztap M O, Öztap P, Aslan S, Adypen H, Önder M.  Comparison of the effects of PUVA and non PUVA treatment on the quality of life of patients with psoriasis vulgaris:  a non-randomized, cross-sectional study. JEADV 2003;  17 (Suppl 1): 59.

79.      Papp K Zitnik R.  Efficacy and safety of ENBREL® (Etanercept) in patients with psoriasis:  results of a global 12-week phase III study.    JEADV  2003; 17 (Suppl 3): 139.

80.      Samgin M A, Monakhov S A.  Adapalene gel 0.1% in the treatment of acne in Moscow.  JEADV  2003; 17 (Suppl 3): 166.

81.      Segard C, Verriere F, Nocera T, Myon E Taieb C.  Impact of hydrotherapy care on the quality of life of patients’ suffering from skin disease.  Quality of Life Research 2003; 12: 777.

82.      Sterodimas A, Nicolaou M, Paes T R F.  Botulinum toxin A injection for forehead hyperhidrosis:  a quality of life study.  Br J Dermatol 2003; 149 (Suppl 64): 107.

83.      Sterry W.  Psoriasis – impact on QoL – efalizumab positive outcomes.  JEADV 2003; 17 (Suppl 3) 439.

84.      Taieb C, Nocera T, Verriere F, Myon E.  Psoriasis and atopic dermatitis:  cross-description of patients’ quality of life. JEADV 2003;  17 (Suppl 1):  38.

85.      Taieb C, Verriere F, Nocera T, Myon E.  Psoriasis and atopic dermatitis:  cross-description of patients’ quality of life.   JEADV  2003; 17 (Suppl 3): 366.

86.      Taieb C, Verriere F, Nocera T, Myon.  Impact of hydrotherapy cares on the quality of life of patients suffering from skin disease.  JEADV  2003; 17 (Suppl 3): 273.

87.      Wong C S M, Sewell M, Yell J.  Nurse practitioners compare favourably with doctors in the treatment of eczema and psoriasis. Br J Dermatol 2003; 149
(Suppl 64):  4-5.

2004

88.      Ahmed Z, David S, Salek M S, Finlay A Y.  Is there a relationship between DLQI scores and quality of life related discussions in dermatology outpatient clinic consultations?  JEADV 2004; 18 (Suppl 2) 535.

89.      Carey W, Menter A, Gilbert M, Gatton D, Rosoph L, Shear N, Langley R.  The effects of 24 weeks of continuous efalizumab therapy on health-related quality of life in patients with moderate to severe chronic plaque psoriasis.  JEADV 2004; 18 (Suppl 1): 49.

90.      Charman C R, Venn A J, Williams H C.  The patient-orientated eczema measure – development and validation of a new tool for measuring atopic eczema severity from the patients’ perspective.  Pead Dermatol 2004; 21 (3): 337.

91.      Chew A-L, Bennett A, Smith C H, Barker J, Kirkham B.  Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.  BJD 2004; 151 (Suppl 68): 55.

92.      Diepgen T L.  Quality of life and contact eczema.  JEADV 2004; 18 (Suppl 2) 98.

93.      Dubertret L, Myon E, Norcera T, Latapie J P, Perez N, Taieb C.  Sunburn and activity.  JEADV 2004; 18 (Suppl 2) 296.

94.     Dubertret L, Myon E, Norcera T, Latapie J P, Perez N, Taieb C.  Sunburn according to gender.  JEADV 2004; 18 (Suppl 2) 29.

95.     Dubertret L, Myon E, Norcera T, Latapie J P, Perez N, Taieb C.  Sunburn and quality of life.  JEADV 2004; 18 (Suppl 2) 535.

96.     Elewski B E, Boh E, Papp K, Zitnik R.  Efficacy and safety of etanercept in patients with psoriasis:  Results of a global phase III study.  J Am Acad Dermatol 2004; 50 (3): P159.

97.     Evers A W M, van den Hoek W, Metsers H, Duller P, Otero M, de Jong E M, van de Kerkhof P C M, Kraaimaat F W.  A short-term, group cognitive-behavioural training for coping with itching and scratching.  JEADV 2004; 18 (Suppl 2) 60.

98.     Feldman S R, Bala M, Menter A, Gordon K B.  The quality of life of patients with severe psoriasis treated with infliximab.  J Am Acad Dermatol 2004; 50 (3): P2.

99.     Feldman S R, Kimball A, Woolley M J, Zitnik R.  Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis.  J Am Acad Dermatol 2004; 50 (3): P155.

100.   Feldman S, Kimball A, Woolley J, Zitnik R.  Etanercept treatment leads to rapid and sustained improvements in the quality of life of patients with moderate to severe psoriasis.  JID 2004; 122: A55.

101.   Ganguly R, Singh A, Sato R.  Etanercept therapy provides clinically meaningful improvement in dermatology quality of life index in patients with chronic plaque psoriasis.  JEADV 2004; 18: 807.

102.   Ganguly R, Van de Kerkhof P, Sterry W, Ortonne J, Randazzo B, Singh A, Wang H.  Improved quality of life with etanercept treatment in patients with chronic plaque psoriasis:  a meta-analytic summary of randomised clinical trials of etanercept.  JEADV 2004; 18: 807.

103.   Gordon K B, Korman N, Frankel E, Zitnik R.  Efficacy of etanercept in an integrated multi-study database of patients with psoriasis.  J Am Acad Dermatol 2004; 50 (3): S101.

104.   Gottlieb A B, Gordon K, Gaspari A A, Randazzo B.  Clinical and pathologic improvements in patients with psoriasis following Etanercept monotherapy.  J Invest Dermatol 2004; 123 (2): A65.

105.   Gradwell C.  A randomized controlled trial of nurse follow-up clinic:  do they help patients and do they free up consultants time?  JEADV 2004; 18 (Suppl 2) 535.

106.   Griffiths C E M, Sterry W, Henninger E.  Safe psoriasis control:  Evaluation of a new approach to assessing efficacy of psoriasis treatments.  J Invest Dermatol 2004; 123 (2): A68.

107.   Griffiths C E M, Sterry W, Henninger E.  Safety control of psoriasis:  evaluation of a new approach to assessing efficacy of psoriasis treatments.  JEADV 2004; 18 (Suppl 2) 355.

108.   Griffiths G, Dubertret L, Berth-Jones J, Strober E B, Yamauchi P, Korman N, Randazzo B.   Etanercept efficacy in patients with psoriasis previously treated with systemic therapy or phototherapy.  JEADV 2004; 18 (Suppl 2) 250.

109.   Helbling I, Ale S, Anda G de.  Use of the validated Spanish version of the Dermatology Life Quality Index questionnaire in Uruguay.  BJD 2004; 151 (Suppl 68): 46.

110.   Hongbo Y, Thomas C L. Harrison M A, Salek M S, Finlay A Y.  Translating the science of quality of life into practice:  what do Dermatology Life Quality Index scores mean?  BJD 2004; 151 (Suppl 68): 46.

111.   J de Korte.  How to improve the quality of life of patients with psoriasis? JEADV 2004; 18 (Suppl 2) 60.

112.   Jacobi A, Schuler G, Hertl M.  Long-term efficacy and safety of TNF-alpha-inhibitor infliximab in severe atopic dermatitis.  J Am Acad Dermatol 2004; 50 (3): P3.

113.   Karaman G, Şahinkarakąs E, Şendur N, Şavk E.  Erythema and scaling or hair loss:  their impact on psychological well-being and quality of life.  JEADV 2004; 18 (Suppl 2) 537.

114.   Katugampola R P, Hongbo Y, Finlay A Y.  Are clinical management decisions related to the impact of psoriasis on patient-related quality of life?  JEADV 2004; 18 (Suppl 2) 156.

115.   Katugampola R P, Hongbo Y, Finlay A Y.  Patient-centred management decisions for psoriasis.  JEADV 2004; 18: 789.

116.   Katugampola R P, Hongbo Y, Finlay A Y.  The relationship between patient-rated quality of life and clinicians’ management decisions in psoriasis – A prospective study.  J Invest Dermatol 2004; 123 (2): A70.

117.   Kimball A, Krueger G, Woolley M J.  The Dermatology Life Quality Index (DLQI) provides qualitatively different information from the PSAI.  J Am Acad Dermatol 2004; 50 (3): P156.

118.   Kowalski J W, Eadie N, Dagget S, Lai P-Y.  Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS).  J Am Acad Dermatol 2004; 50 (3): P51.

119.   Krueger G G, Woolley M J, Zitnik R.  The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis.  J Am Acad Dermatol 2004; 50 (3): P155.

120.   Krueger G, Woolley J, Zitnik R.  Clinically meaningful improvements in patient-reported outcomes for patients with moderate to severe psoriasis receiving etanercept.  JID 2004; 122: A55.

121.   Lambert J, de la Brassinne M, Myon E, Martin N, Monnier F, Weckx H, Bloome S A, Taieb C H.  Living with a dermatosis: a national survey of quality of life in Belgium.  JEADV 2004; 18 (Suppl 2) 150.

122.   Lewis V J, Chowdhury M M U, Statham B N.  Natural rubber latex allergy:  impact on lifestyle and quality of life.  BJD 2004; 151; (Suppl 68): 113.

123.   Lewis V J, Statham B, Chowdhury M.  How does the diagnosis of latex allergy affect peoples’ lives?  J Am Acad Dermatol 2004; 50 (3): P66.

124.   Liangcai W, Nianzu L.  The correlative study on quality of life in vitiligo patients and its influencing factors.  Qual Life Research 2004; 13(9): 1589.

125.   Liangcai W.  Pilot study on quality of life of vitiligo patients from South China with Cantonese version of the DLQI and a self-developed questionnaire.  Qual Life Research 2004; 13(9): 1589.

126.   Ling T C, Richards H L, Brownrigg M, Huber K, Brooke R C C, Gibbs N K, Rhodes L R.  Psychological distress in polymorphic light eruption.  BJD 2004; 151; (Suppl 68): 104.

127.   McMichael A J, Balkrishnan R, Bouloc A, Feldman S.  Impact of corrective cosmetic use on health-related quality of life in women with severe facial pigmentary disorders.  J Am Acad Dermatol 2004; 50 (3): P78.

128.   McKenna SP, Meads DM, Doward LC. Scaling properties of the Dermatology Life Quality Index (DLQI). Value Health 2004; 7:750-751.

129.   Meding B, Wallenhammar L-M, Lindberg M, Nyfjall M. Health-related quality of life and hand eczema. Contact Dermatitis 2004; 50(3): 152-153.

130.   Menter A, Hamilton T, Caro I, Chen-Rundle A.  Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis:  Pooled results from three randomized phase III trials.  J Am Acad Dermatol 2004; 50 (3): P156.

131.   Myon E, Dubertret L, Nocera T, Latapie J P, Taieb C.  Sunburns and quality of life.  JEADV 2004; 18 (Suppl 1): 77.

132.   Myon E, Dubertret L, Nocera T, Latapie J P, Taieb C.  Sunburns and activity.  JEADV 2004; 18 (Suppl 1): 76.

133.   Nash P, Thaci D, on behalf of the TOPAS Study Group.  The impact of Leflunomide on skin symptoms in patients with psoriasis and psoriatic arthritis.  JEADV 2004; 18 (Suppl 1): 78.

134.   Naumescu E, Balasoiu V, Mihai D, Chelemen M. Coman O.  Experience with oral contraceptives in the treatment of acne vulgaris.  JEADV 2004; 18 (Suppl 2) 203

135.   Naumescu E, Balasoiu V, Mihai D, Chelemen M. Coman O.  Experience with diane-34® in the treatment of acne vulgaris.  JEADV 2004; 18 (Suppl 2) 204.

136.   Nicolaidou E, Antoniou Ch, Avgerinou G, Stratigos A, Stravropoulos E, Potouridou E, Katsambas A D.  Cyclosporine improves the quality of life of psoriasis patients.  JEADV 2004; 18 (Suppl 2) 296.

137.   Ortonne J-P, Sterry W, Shear N, Shumack S, Duru G, Beresniak A.  Impact of Efalizumab on health-related quality of life outcomes in patients with moderate to severe chronic plaque psoriasis:  Results of the international randomized controlled phase II clinical experience acquired with Raptiva (CLEAR) trial.  J Invest Dermatol 2004; 123 (2): A67.

138.   Randazzo B, Griffiths C E M, Dubrett L, Meurer M.  Etanercept monotherapy is safe and efficacious in patients with psoriasis:  results of a worldwide phase III study.  JEADV 2004; 18 (Suppl 1): 87.

139.   Randazzo B, Griffiths C, Dubetret L, Meurer M.  Safety and efficacy results of a phase 3 study of etanercept monotherapy in patients with psoriasis.  JEADV 2004; 18: 806.

140.   Randazzo B, Prens E P, Rustin M.  Patient-reported outcomes improve significantly in psoriasis patients receiving etanercept therapy.  JEADV 2004; 18 (Suppl 1):  87.

141.   Randazzo B, Prens E, Rustin M.  Significant improvement in patient-reported outcomes in psoriasis patients on etanercept therapy.  JEADV 2004; 18: 807.

142.   Randazzo B, van der Kerkhof P C M, Sterry W, Ortonne J-P, Berth-Jones J. Efficacy of etanercept in patients with psoriasis:  results of an integrated multi-study analysis.  JEADV 2004; 18 (Suppl 1):86.

143.   Randazzo B, Van der Kerkhof P, Sterry W, Ortonne J, Berth-Jones J.  Efficacy of etanercept in psoriasis:  an analysis of pooled data from multiple studies.  JEADV 2004; 18: 784.

144.   Reitamo S, on behalf of the UK Tacrolimus Ointment Study Group.  Quality of life improved in adults with moderate to severe atopic dermatitis treated with 0.1% tacrolimus ointment.  JEADV 2004; 18 (Suppl 1): 88.

145.   Rustin M, on behalf of the UK Tacrolimus Ointment Study Group. Pharmacoeconomics of 0.1% ointment in adults and children with moderate to severe atopic dermatitis.  JEADV 2004; 18 (Suppl 1): 90.

146.   Salek S, David S.  An evaluation of the relevance of HRQoL discussion in outpatient consultation to the level of impairment as measured by the DLQI.  Qual Life Research 2004; 13(9): 1522.

147.   Schmitt J, Wozel G. Combination therapy of leflunomide and etanercept in psoriatic-arthritis.  JEADV 2004; 18: 805.

148.   Schöffski O, Sohn S.  Cost of moderate to severe plaque psoriasis in Germany.  JEADV 2004; 18 (Suppl 2) 158.

149.   Seidenari S, Guisti F, Cirillo A, Amoroso S, Flori M  L, Amerio P, Ricciuti F, Vena G A, Cristaudo A, Le Grazie C & the Italian Study Gropu on DL in Chronic Urticaria. Desloratadine (DL) improves the quality of life (QoL) in patients with chronic urticaria (CU).  JEADV 2004; 18 (Suppl 2) 552.

150.   Singh A, Ganguly R, Sato R.  Clinically meaningful improvement in Dermatology Life Quality Index in patients with chronic plaque psoriasis:  A meta-analytic summary of randomized clinical trials of Etanercept.  J Invest Dermatol 2004; 123 (2): A69.

151.   Singh A, Ganguly R, Sato R.  Clinically meaningful improvement in dermatology life quality index in patients with chronic plaque psoriasis  a meta-analytic summary of randomized clinical trials of etanercept.  JEADV 2004; 18 (Suppl 2) 354.

152.   Sladden M J, Mortimer N J, Hutchinson P E.  Severe, refractory, chronic plaque psoriasis successfully treated with adalimumab (Humira ®).  BJD 2004; 151 (Suppl 68): 55.

153.   Spalding J R, Kowalski J, Lee J, Glaser D A.  Effect of pharmacologic treatment on dermatologic-specific quality of life (QoL):  A comparison of botulinum toxin type–A (BT-A) for primary focal hyperhidrosis (HH) to medical treatments for other dermatological diseases.  J Am Acad Dermatol 2004; 50 (3): P51.

154.   Spalding J, Hamm H, Naumann M, Lee J T, Kowalski J W.  Literature review and comparison of the dermatology-specific quality of life effect of primary focal hyperhidrosis and improvement following treatment with botulinum toxin type-A (BTX-A)  JEADV 2004; 18 (Suppl 1): 97.

155.   Sterry W, Dubetret L, Larsen C, Chimetin S.  Safe psoriasis control:  a comprehensive evaluation of psoriasis treatment efficacy analysed in a multinational, randomised, placebo-controlled, phase II clinical trial for efalizumab.  JEADV 2004; 18: 808.

156.   Stone S, Papp K, Caro I, Bresnahan B.  Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis.  J Am Acad Dermatol 2004; 50 (3): P157.

157.   Strober B E, Yamauchi P, Korman N, Stevens S.  Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy.  J Am Acad Dermatol 2004; 50 (3): P147.

158.   Strober B, Yamauchi P, Korman N, Xia H, Stevens S.  The efficacy of etanercept in psoriasis patients with varying treatment histories.  JID 2004; 122: A43.

159.   Suchan M, Jenisch S, Budahl R, Christophers E, Weichenthal M.  Objective severity measures and quality of life in patients with psoriasis.  J Invest Dermatol 2004; 123 (2): A67.

160.   Taieb C H.  Living with a dermatosis: a national survey of quality of life in Belgium.  JEADV 2004; 18 (Suppl 2) 150.

161.   Taieb C, Finlay A Y, Nocera T, Verriere F, Martin N, Myon E.  Impact of hydrotherapy programme on the quality of life of patients suffering from psoriasis.  JEADV 2004; 18: 811.

162.   van der Ham R, Shumack S, Duru G, Beresniak A.  Effects of efalizumab on health-related quality-of-life outcomes:  an international phase III randomized, controlled trial of patients with moderate to severe chronic plaque psoriasis.  JEADV 2004; 18 (Suppl 1): 103.

163.   van der Kerkhof P C M, Randazzo B, Krueger G G, Lebwhol M G, Jahreis A. Etanercept therapy continued after early incomplete response in patients with psoriasis.  JEADV 2004; 18 (Suppl 2) 146.

164.   van der Kerkhof P C M,  Sterry W, Ortonne J-P, Randazzo B, Singh A, Ganguly A, Wang H.  Etanercept improves quality of life of patients with chronic plaque psoriasis:  a meta-analytic summary of randomized clinical trails of etanercept.  JEADV 2004; 18 (Suppl 2) 353.

165.   van der Kerkhof P C M, Sterry W, Ortonne J-P, Berth-Jones J, Randazzo B. Etanercept efficacy results from an integrated multi-study in patients with psoriasis.  J Invest Dermatol 2004; 123 (2): A65.

166.   van der Kerkhof P C M, Sterry W, Ortonne J-P, Berth-Jones J, Randazzo B. Etanercept efficacy results from an integrated multi-study in patients with psoriasis.  JEADV 2004; 18 (Suppl 2) 248.

167.   van der Kerkhof P C M, Sterry W, Ortonne J-P, Randazzo B, Singh A, Ganguly R, Wang H.  Etanercept improves quality of life of patients with chronic plaque psoriasis:  a meta-analytic summary of randomized clinical trials of Etanercept.  J Invest Dermatol 2004; 123 (2): A69.

168.   Vena G A, Cassano N, Seidenari S, Guisti F, Schroeder J W, Zichichi L, Mosca M, Pezzuto F, Criseta V, Troise C, Pigatto P, Lembo G, Stingeni L, De Pita O, Le Grazie C & the Italian Study Group on DL in Chronic Urticaria.  Desloratadine (DL) improves the quality of life (QoL) and symptoms in patients with moderate and severe chronic urticaria (CU).  JEADV 2004; 18 (Suppl 2) 552.

169.   Wain E M, Ronda L, Barker J N W N, Smith C H.  Prospective, open, nonrandomized study investigating efficacy and safety of fumaric acid esters in a cohort of patients with severe, recalcitrant, chronic plaque psoriasis.  BJD 2004; 151 (Suppl 68): 6.

170.   Wallace K, Chen D, Heffernan M, Langley R, Menter A.  Quality of life in moderate to severe plaque psoriasis patients receiving 24 weeks of adalimumab therapy.  JEADV 2004; 18 (Suppl 2) 359.

171.   Woo P N, White M I.  A family study of erythrokeratoderma variabilis. BJD 2004; 151 (Suppl 68): 71.

172.   Zaghloul S S, Goodfield M J D.  Objective assessment of compliance with different topical therapies in psoriasis.  BJD 2004; 151 (Suppl 68): 52.

173.   Zaghloul S S, Goodfield M J D.  The influence of nurse education clinics as a supplementary technique on compliance in psoriasis.  BJD 2004; 151 (Suppl 68): 51.

2005

174.   Agredano Y, Alster T S, Bryan H A, Weiss S C.  Quality of life assessment of patients with port-wine stains receiving flashlamp-pulsed dye laser treatment.  J Am Acad Dermatol 2005; 52(Suppl 1): 210.

175.   Ammad S, Gonzales M, Edwards C, Finlay A Y.  An assessment of blue light phototherapy in the treatment of acne vulgaris.  Nouv Dermatol 2005; 24 (Suppl 7): 18.

176.   Baron S E, Layton A, Goulden V.  A pilot study of hypnotherapy to treat adults and children with moderate to severe atopic dermatitis.  BJD 2005; 153 (Suppl 1): 37.

177.   Baron S E, Morris P K, Dye L, Fielding D, Goulden V.  The effect of dermatology consultations in secondary care on treatment outcome and quality of life in adult patients with atopic dermatitis.  BJD 2005; 153 (Suppl 1): 8.

178.   Blanchet-Bardon C, Corre J-M, Le C N. Health-related quality of life in ichthyosis patients and family members.  J Am Acad Dermatol 2005; 52(Suppl 1): 110.

179.   Cusack C, Buckley C.  Etanercept  effective in the management of hidradenitis suppurativa.  BJD 2005; 153 (Suppl 1): 4.

180.   Finlay A Y.  Unidimensionality of the DLQI – confirmed at last.  Acta Derm Venereol 2005; 85: 385.

181.   Frankel E, Fivenson D, Yu E, Stevens S R.  Improvements in health-related quality of life in psoriatic arthritis patients on etanercept:  results from EDUCATE, an open-label study of etanercept patients treated by dermatologists.  J Am Acad Dermatol 2005; 52 (Suppl 1): 188.

182.   Gottlieb A, Woolley J M, Lalla D, Jahreis A.  Treatment with etanercept improves patient-reported outcomes in patients with moderate to severe psoriasis.  J Am Acad Dermatol 2005; 52 (Suppl 1): 201.

183.   Guitera P, Taieb C, Myon E, Dubretret L.  Sunburn and quality of life.  J Am Acad Dermatol 2005; 52 (Suppl 1): 109.

184.   Guitera P, Taieb C, Myon E, Dubretret L.  Sunburns according to gender.  J Am Acad Dermatol 2005; 52 (Suppl 1): 108.

185.   Guitera P, Taieb C, Myon E, Dubretret L.  Sunburns and activity.  J Am Acad Dermatol 2005; 52 (Suppl 1): 108.

186.   Hamm H, Naumann M, Kozma C, Kowalski J.  Primary focal hyperhidrosis:  comparison of functional imparirment, health-related quality of life, and medical history across a large cohort of patients by focal location and nonhyperhidrotic controls.  J Am Acad Dermatol 2005; 52 (Suppl 1): 57.

187.   Holme S A, Anstey A V, Badminton M N, Elder G H.  UK prospective study on erythropoietic protoporphyria:  quality of life assessment.  BJD 2005; 153
(Suppl 1): 41

188.   Katugampola R P, Thomas C L, Hongbo Y, Salek M S, Finlay A Y.  Psoriasis decision taking and the Dermatology Life Quality Index bands.  BJD 2005; 153; 475.

189.   Katugampola R, Hongbo Y, Finlay A Y.  Patient-rated quality of life and clinicians’ management decisions over psoriasis:  a prospective study.  J Am Acad Dermatol 2005; 52 (Suppl 1): 105.

190.   Kimball A, Chang A L S, Badger J.  Alefacept for moderate to severe lichen planus.  J Am Acad Dermatol 2005; 52 (Suppl 1): 45.

191.   Lambert J, de la Brassinne M, Myon E, Taieb C.  Living with a dermatosis:  a national survey of depressive symptomatology in Belgium.  J Am Acad Dermatol 2005; 52
(Suppl 1): 104

192.   Lambert J, de la Brassinne M, Myon E, Taieb C.  Living with a dermatosis: a national survey of quality of life in Belgium.  J Am Acad Dermatol 2005; 52 (Suppl 1) 105.

193.   Leonardi C, Feldman S R, Hamilton T K, Stevens S R. DLQI and PASI improve together initially and during re-treatment with etanercept. J Am Acad Dermatol2005; 52 (Suppl 1): 180.

194.   Ling T C, Richards H L, Janssen A S, Aubin F, Jansen C, Anastassopoulou, Stratigos A J, Antoniou C, Deipgen T L, Gibbs N K, Rhodes L E.  Impact of polymorphic light eruption on quality of life across four seasons and at a range of latitudes in Europe.  BJD 2005; 152: 853.

195.   Moloney E J, Keane S, O’Kelly P, Conlon P J, Murphy G M.  The impact of skin disease on quality of life following renal transplantation.  BJD 2005; 153 (Suppl 1): 41.

196.   Pearce D, Nelson A, Fleischer A, Balkrishnan R.  How much for one unit of DLQI improvement?  A costs-effectiveness analysis of biologics in psoriasis.  J Am Acad Dermatol 2005; 52 (Suppl 1): 186.

197.   Reich K, Nestle F, Ortonne J P, Papp K, Evans R, Guzzo C, Li S, Dooley L, Griffiths C E M.  Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy.  BJD 2005; 153 (Suppl 1): 4.

198.   Salek S, Patel C, Davies E, Finlay A Y.  Are dermatology outpatient clinic    consultations patient-centred?  Qual Life Research 2005; 14((9):  2045.

199.   Schmitt J, Pfeiffer C, Heese E, Wozel G, Neurer M.  Prospective study on the long-term effect of in-patient treatment on quality of life and clinical severity in atopic dermatitis and psoriasis vulgaris.  JID 2005; 125 (Suppl):  A78.

200.   Shikiar R, Harding G, Leahy M, Lennox R D.  Minimal Important Difference (MID) of the Dermatology Life Quality Index  (DLQI):  Results from patients with chronic idiopathic urticaria.  Health Qual Life Outcomes 2005; 3(1): 36.

201.   Strober B, Crowley J J, Woolley J M, Stevens S R.  Twice as nice:  Dual impact of etanercept treatment on skin and joint patient-reported outcomes of psoriatic arthritis patients from the experience, diagnosing, understanding care and treatment with etanercept (EDUCATE) trial.  J Am Acad Dermatol 2005; 52 (Suppl 1): 201.

202.   Szepietowski J C, Hrehorow E, Reich A.  Importance of itching on the feeling of stigmatization among psoriatic patients.  Acta Derm Venereol 2005; 85: 467.

203.   Taieb C, Finlay A Y, Nguyen C, Myon E.  Adults with atopic dermatitis:  quality of life impact.  J Am Acad Dermatol 2005; 52 (Suppl 1): 66.

204.   Thomas C, Hongbo Y, Salek S, Finlay A Y.  A global question approach to aid interpretation of DLQI scores.  J Am Acad Dermatol 2005; 52 (Suppl 1): 102.

205.   Van Coevorden A M, Van Sonderen E, Bouma J, Coenraads P J.  Assessment of severity of hand eczema and discrepancies between patient and physician-related scores.  JID 2005; (Suppl): A78.

206.   Wallace K, Gordon K, Langley R, Chen D.  Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy.  J Am Acad Dermatol 2005; 52 (Suppl 1): 180.

207.   Wallace K, Langley R, Bissonnette R, Chen D.  Quality of life in patients with psoriatic arthritis treated with adalimumab:  sub-analysis of studies moderate to severe psoriasis.  J Am Acad Dermatol 2005; 52 (Suppl 1): 192.

2006

208.   Weber M, Mazzotti N, Barzenski B, Silva T.  Evaluation of the quality of life in patients with atopic dermatitis participating in support groups.  J Am Acad Dermatol 2005; 52 (Suppl 1): 70.

209.   Baron S, Layton A, Goulden V.  A Pilot study of hypnotherapy to treat adults and children with moderate to sever atopic dermatitis.  J Am Acad Dermatol 2006; 54:  AB2.

210.   Basra M K A, Su-Ho R, Finlay A Y.  Psychometric properties of the FDLQI:  a novel dermatology specific quality of life measure for the families of dermatology patients.  BJD 2006; 155 (Suppl 1): 7.

211.   Camp B, Pennie M, Harris K, Traywick C, Chen S.  Comparison of two skin disease-specific quality of life questionnaires:  DLQI vs Skindex.  JID 2006; 125 (322).

212.   Cassano N, Loconsole F, Galluccio A, Icracapillo A, Pezza M, Vena G A.  Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis:  results of a pilot experience (power study).  Int J immunopathol Pharmacol 2006; 19(1): 225-229.

213.  Conway P, Reeves P, Lloyd A, Baxter G.  Cost effectiveness of etanercept in patients with plaque psoriasis meeting BAD criteria for biological interventions.  BJD 2006; 155
(Suppl 1): 33.

214.  Davies E, C Patel, Salek S, Finlay A.  Quality of life discussion and patient satisfaction in inflammatory skin disease consultations.  J Am Acad Dermatol 2006; 54:  AB120

215.  Eghlileb A, Davies E, Finlay A.  Psoriasis has significant impact on relatives and partners of patients with psoriasis.  J Am Acad Dermatol 2006; 54:  AB206.

216.  Feldman S, McCarty A, Pearce D, Fleischer A.  Safety and efficacy of an extended course of high-does (30 mg) Alefacept in combination with UVB.  J Am Acad Dermatol 2006; 54:  AB224.

217.  Ferraz L B, de Almeida F A, Vasconcellos M R A, Ferraz M B.  Alopecia impairs the quality of life of patients with lupus erythematosus. Arch Dermatol 2006; 142: 110.

218.  Gelfand J, Kimball A, Mostow E, Chiou F.  Health resource utilization and patient-reported outcomes during continuous and intermittent treatment with etanercept:  6-month results.  J Am Acad Dermatol2006; 54:  AB219.

219.  Gladman D, Mease P, Kavanaugh A, Weinberg M.  Adalimumab is efficacious in treating skin disease in psoriatic arthritis:  sub-analysis of moderate versus severe psoriasis in the ADEPT trial.  J Am Acad Dermatol 2006; 54:  AB10.

220.  Gordon K B, Langley R G, Leonardi C, Menter M A, Okun M M, McIllraith.  Efficacy and safety of adalimumab treatment of chronic plaque psoriasis in patients who meet some criteria for biological interventions in accordance with British Association of Dermatologists guidelines.  BJD 2006; 155 (Suppl 1): 32.

221.  Holme S A, Anstey A V, Finlay A Y, Elder G H, Badminton M N. Epidemiology of erythropoietic protoporphyria:  the UK experience.  BJD 2006; 155: 866.

222.  Japiassu M A, Fagundes F, Carneiro S, Pereira F.  The impact of psoriasis on quality of life:  Use of the DLQI and PDI questionnaires.  J Am Acad Dermatol 2006; 54:  AB208

223.  Katugampola R, Lewis V J, Finlay A Y.  A review of the Dermatology Life Quality Index  in assessing the efficacy of biological treatments in psoriasis.  BJD 2006; 155 (Suppl 1): 34.

224.  Houl D K,  Korman N J.  The safety and efficacy of Alefacept dose escalation in patients with moderate to severe plaque psoriasis:  Results of an open-label study of Alefacept 15 mg 6 weeks followed by 30 mg for 6 weeks.  J Am Acad Dermatol 2006; 54:  AB226.

225.    Krishnan R, Cella D, Jahareis A, Chiou F, Walker S, Molta C, Foehl J.  Sustained improvement in symptoms of depression and other patient reported outcomes for up to 48 weeks in chronic plaque psoriasis patients treated with etanercept.  JID  online.

226.    Lynde C, Kunynetz R, Guenther L, Carey W.  A phase III, randomized, multicentre, double-blind, placebo-controlled quality of life study of ISA 247 in plaque psoriasis patients.  J Am Acad Dermatol 2006; 54:  AB210.

227.    Melilli L, Shikiar R, Thompson C.  Minimum clinically important difference in Dermatology Life Quality Index  in moderate to severe plaque psoriasis patients treated with Adalimumab.  J Am Acad Dermatol 2006; 54:  AB221.

228.    Melilli L, Zhong J, Finlay A.  Raid improvement in functional limitations of patients with moderate to severe chronic plaque psoriasis treated with Adalimumab.  J Am Acad Dermatol 2006; 54:  AB223.

229.    Menter A, Papp K, Guzzzo C.  Pooled efficacy of infliximab for the treatment of patients with moderate to sever psoriasis.  J Am Acad Dermatol 2006; 54:  AB222.

230.    Menter A.  Focal plantar hyperhidrosis:  A review plus evaluation of new fabric shoe liner.  J Am Acad Dermatol 2006; 54:  AB67.

231.    Papoutsaki M, Bianchi L, Chimenti M S, Chimenti S.  Adalimumab in the treatment of psoriasis and psoriatic arthritis: ongoing results.  J Am Acad Dermatol 2006; 54:  AB199.

232.    Reid D, Mosam A.  Quality of life in patients with HIV skin disease.  J Am Acad Dermatol 2006; 54:  AB60

233.    Taieb C, Corvest M, Voisard J J, Myon E.  Nail psoriasis: Elaboration of a scale for functional bother.  J Am Acad Dermatol 2006; 54:  AB204.

234.    Taieb C, Corvest M, Voisard J J, Myon E.  Nail psoriasis:  impact on quality of life.  J Am Acad Dermatol 2006; 54:  AB129

235.    Taieb C, Nguyen C, Myon E.  Adults with atopic dermatitis:  quality of life impact. J Am Acad Dermatol 2006; 54:  AB80

236.    Weatherhead S, Wahie S, Reynolds N J, Meggitt S J.  Methotrexate for moderate to severe atopic eczema.  BJD 2006; 155 (Suppl 1):44.

237.    Yang C-W, Su L-M, Feng W-W, Chen T-J.  Emotional distress and related factors in patients with acne.  J Am Acad Dermatol 2006; 54:  AB1

238.    Yones, SS; Palmer, R A; Garibaldinos T; Hawk JL.A prospective randomised double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP). Photodermatology, Photoimmunology & Photomedicine 2006; 22(4): 222.

239.    Yones SS; Palmer RA; Garibaldinos T; Hawk JL. A prospective randomised double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of vitiligo.Photodermatology, Photoimmunology & Photomedicine 2006. 22(4):223.

240.    Yones SS; Palmer RA; M. Hawk JL. Improvement in quality of life in psoriasis is correlated with the improvement in psoriasis area and severity index that occurs with phototherapy. Photodermatology, Photoimmunology & Photomedicine 2006. 22(4):223.

2007

241.    Abdul Ghafffar S. Finlay A Y.  Moral and cost dilemma of a psoriasis patient. BJD 2007; 156:186-187.

242.    Aghaei S, Safaee G, Ardenkani.  Impact of psoriasis on quality of life in Iran. JEADV 2007; 21 (Suppl 1):32.

243.    Basra M K A, Finlay AY. Age, gender, disease duration of self-assessed disease severity: which is the best predictor of dermatological patients’ quality of life? JID 2007 (On-line Suppl).

244.    Basra M K A, Finlay A Y.  Eczema has greater impact than acne on the quality of life of patients’ families.  J Am Acad Dermatol 2007;

245.    Basra M K A, Finlay A Y.  quality of life of patients and their families is related to the self-assessed severity of patients’’ skin disease.  .  Br J Dermatol 157 (Suppl 1):  56.

246.    Basra M K A, Su-Ho R, Finlay A Y.  Impact of patients’ psoriasis on the quality of life of their families:  initial results from a validation study of a novel dermatology-specific measure.  J Investig Dermatol 2007, 127: 1808.

247.    Boixareu M J T, Turroja M, Gallardo F, Ros S, Bulbena A, Pujol R M.  The association between psoriasis and stress:  a prospective study in 206 patients.  Dermatologia Kliniczna 2007; 9 (Suppl 1):  45

248.    Campione E, Paterno E J, Diluvio L, Chimenti S.  Botulinum neurotoxin serotype A:  Italian experience in axillary focal idiopathic hyperhidrosis.  J Am Acad Dermatol 2007; February AB197.

249.     Chrostowska-Plak D, Reich A, Szepietowski J C.  The influence of itching on atopic dermatitis patients’’ well-being.  Dermatologia Kliniczna 2007; 9 (Suppl 1): 22.

250.    Dabbous O, Rahman M, Arjunji r, McMonigle S, Files C, Tang B, Thompson H, Stang P.  Moderate-severe psoriasis sufferers’ disease burden and satisfaction with treatment:  findings from a patient survey.  JEADV 2007; P1089.

251.    Eghlileb A M, Finlay A Y.  Assessment of patients’ psoriasis severity by relatives and partners.  JEADV 2007; 21 (Suppl 1): 30.

252.    Eghlileb A M, Finlay A Y. Responsiveness of the Psoriasis Family Index (PFI-20) Instrument to treatment of family member’s psoriasis. Quality of Life Research 2007.

253.    Gajur A, Schaefer I, Augustin M.  Health care assessment of patients with vitiligo in Germany.  JEADV 2007; P411.

254.    Abdul Ghafffar S. Finlay A Y.  Moral and cost dilemma of a psoriasis patient. BJD 2007; 156:186-187.

255.    Gladman D, Mease P, Richlin C, Okum M.  PASI 100 is associated with better dermatology-specific patient reported outcomes compared with PASI 75-99 in Adalimumab-treated patients with psoriatic arthritis:  Subanalysis of ADEPT.   JEADV 2007; P1107.

256.    Gladman D, Mease P, Ritchlin C, Okun M.  PASI-100 is associated with better dermatologic-specific patient-reported outcomes compared with PASI-75-99 in Adalimumab-treated patients with psoriatic arthritis:  Subanalysis of ADEPT.  J Am Acad Dermatol 2007; February AB185.

257.    Glaser D E, Kowalski J, Ravelo A, Weng E.  Functional and dermatologic-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years.  J Am Acad Dermatol 2007; February AB58.

258.    Gordon K, Kimball A, Langley R, Okun M.  PASI-100 is associated with better dermatology-specific reported outcomes compared with PASI-75:  Subanalysis of a phase II psoriasis trial of Adalimumab.  J Am Acad Dermatol2007; February AB186.

259.    Gottlieb A B, Frankel E H, Strober B E, Fivenson D, Stevens S R.  Clinical efficacy, safety and patient-reported outcomes of EDUCATE, a multi-centre, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis. Investig Dermatol 2007, 127:  1824.

260.    Idriss S Z, Kvedar J C, Watson A J.  Psoriases e-communities:  exploring the benefits of online support.  JID online (Suppl 63).

261.    Jaworek A, Domagala M, Bucka K, Wojas-Pelc A.  Life quality assessment by patients suffering from vitiligo treated.  Dermatologia Kliniczna 2007; 9 (Suppl 1):  48.

262.    Jaworek A, Domagala M, Bucka K, Wojas-Pelc A.  Life quality assessment by patients suffering from acne vulgaris and. acne  Dermatologia Kliniczna 2007; 9 (Suppl 1):  49.

263.    Jong C T, Finlay A Y, Anstey A V, Pearse AD, Kerr A C, Ferguson J, Benton E C, Hawk J L M, Sarkany R P, McMulllen E, Rhodes L E Farr P M.  The quality of life of 797 patients with photodermatoses.  Br J Dermatol 157 (Suppl 1):  10.

264.       Marron S, Tomas L, Perez C, Dieste L, Gascon J L.  Anxiety, depression, quality of life and patient satisfaction in acne patients treated with oral Isotretinoin.  Dermatologia Kliniczna 2007; 9 (Suppl 1): 21

265.    Kanikowska A, Pawlaczyk M, Rokowska A.  Quality of life in psoriasis patients. Dermatologia Kliniczna 2007; 9 (Suppl 1):  47.

266.    Khoudri I, Rmili M, Ismaili N, Hassam B, Zeggwagh A, Abouqal R.  The Arabic version of the Dermatology Life Quality Index for Morocco:  a study of reliability and validity in psoriatic.  JEADV 2007; 21 (Suppl 1): 31.

267.    Kircik L, Bagel J, Korman N, Menter A, Elmets C, Stevens S.  Utilization of narrow-band UVB light therapy and etanercept for the treatment of psoriasis (UNITE):  efficacy, safety and patient-reported outcomes.  JEADV 2007; P1120.

268.    Koo J.  Quality of life results from a large community-based trial assessing clobetasol propionate 0.5% spray as monotherapy and add-on therapy.  J Am Acad Dermatol 2007; February AB187.

269.    Kowalksi J, Ravelo A, Weng ESlaton T.  Minimal important difference (MID) of the Dermatological Life Quality Index in patients with axillary and palmar hyperhidrosis.  J Am Acad Dermatol 2007; February AB52.

270.    Langley R G, Saurat J, van de Kerkhof P, Mrowietz U, Okun M.  Improvement in dermatology-specific quality of life with Adalimumab treatment:  Results from CHAMPION.  JEADV 2007; P1147.

271.    Mak R, Cerio R.  Improved efficacy of efalizumab as adjunctive therapy in moderate to severe psoriasis:  short term and maintenance safety data in 10 patients.  .  Br J Dermatol 157 (Suppl 1):  50.

272.    Marron S, Tomas L, Perez C, Dieste L, Gascon J L.  Anxiety, depression, quality of life and patient satisfaction in acne patients treated with oral Isotretinoin. Dermatologia Kliniczna 2007; 9 (Suppl 1): 21

273.    Mazharinia A, Aghaei S. Dermatology Life Quality Index (DLQI) scores in burn victims after revival. Quality of Life Research 2007

274.    Murrell D F, Calvieri S, Ortonne J-P, Ho V C, Weise-Riccardi S, Glendenning A, Paul C F.  Quality of life outcomes in a randomized controlled trial of pimecrolimus cream 1% in patients with head & neck atopic dermatitis who are intolerant of, or dependant on topical corticosteroids.  JEADV 2007; P59.

275.    Nikolayevich N R, Vladimirovich SS A.  Psychotherapy in dermatology. Dermatologia Kliniczna 2007; 9 (Suppl 1):  43.

276.    Papoutsaki M, Chimenti M S, Costanzo A, Talamonti M, Zangrilli A, Guinta A, Bianchi L, Chimenti S.    Adalimumab for severe psoriasis and psoriatic arthritis:  an open label study in 30 patients previously treated with other biologics.  JEADV 2007; 21 (Suppl 1): 55

277.    Papoutsaki M, Chimenti M S, Talamonti M, Chimenti S.  Long-term efficacy of Adalimumab for the treatment of psoriasis and psoriatic arthritis.  J Am Acad Dermatol 2007; February AB175.

278.    Reich A, Hrehorow E, Szepietowski J C. Negative influence of itching on psoriatic patients’ well-being (P25). Acta Derm Venereol 2007.

279.    Reich A, Hrehorow E, Szepietowski.  Quality of life of patients with psoriasis:  relation with pruritus, stress and symptoms of depression.  Dermatologia Kliniczna 2007; 9
(Suppl 1):  47.

280.    Sato R, Milligan G, Molta C, Singh A.  Poor quality of life is associated with increased healthcare resource utilization independent of disease severity in plaque psoriasis patients.  J Am Acad Dermatol 2007; February AB183.

281.    Serban A, Gottlieb A, Woolley J M, Lalla D, Jahreis A.  Patient reported outcomes show improvement within 1 week in patients with psoriasis following etanercept treatment.  Investig Dermatol 2007, 127:  1809.

282.    Szepietowski J C, Reich A, Wesolowska-Szepietowska E, Baran E.  Quality of life in patients suffering from seborheic dermatitis:  influence of age, gender and education level.  Dermatologia Kliniczna 2007; 9 (Suppl 1):  41.

283.    Szepietowski J C, Reich A, Wozniak M, Baran E.  Evaluation of quality of life in patient with onychomycosis using a Polish version of the Dermatology Life Quality Index.  Dermatologia Kliniczna 2007; 9 (Suppl 1):  50.

284.    Szepietowski, J Susel.  Influence of uremic pruritus on patients’ well being. Dermatologia Kliniczna 2007; 9 (Suppl 1):  30.

285.    Tyring S, Poulin Y, Langley R, Gordon K, Gottlieb A, Dunn M, Jahreis A.  A 96-week phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis.  JEADV 2007; P1115.

286.    Wollenberg A, Sidhu M K, Odeyemi I, Dorsch B, Koehne-Volland R, Ehiken B, Berger K.  Quality of life in patients with moderate or severe atopic dermatitis receiving prophylactic tacrolimus ointment treatment.  JEADV 2007; P66.

287.    Wu Y, Eisenberg D, Bala M.  Infliximab improves patient quality of life in presence of comorbidities.   JEADV 2007; P1077.

288.    Wu Y, Li S, Eisenberg D, Guzzo C.  Consistency in DLQI improvement among subgroups in infliximab-treated psoriasis patients.  J Am Acad Dermatol 2007; February AB179.

289.    Zhu X, Lan C-C, Kim K H, Tay Y-K, Noppakun N, Hussein S H, Sarrosa D L, Soegito T L.  Efficacy and safety of tacrolimus ointment in atopic dermatitis patients in Asia.  JEADV 2007; P69.

2008

290.    Taieb C, Martinsic M A, Nocera T, Bousetta S.  Atopic dermatitis and thermal therapy:  evaluation of medical service.  J Am Acad Dermatol (February) 2008; AB50, P611.

291.    Taieb C, Ambonati M, Macy G, Bousetta S.  Atopic dermatitis impact on the quality of life of patients and patients’ spouses.  J Am Acad Dermatol (February) 2008; AB53, P621.

292.    Hackett K, DeLong L, Camp B, Chen S.  Are there racial disparities in health-related quality of life in patients with skin disease?  J Am Acad Dermatol (February) 2008; AB76, P1200.

293.    Ortonne J-P, Reich K, Keiningr D.  Certolizumab pegol improved health-related quality of life in patients with psoriasis:  Data from a phase II study.  J Am Acad Dermatol (February) 2008; AB121, P2617.

294.    van der Kerkhol P, Paolozzzi L, ajdula J, Lahfa M. Etanercept 50mg once weekly is effective and well tolerated in patients with moderate to severe plaque psoriasis.  J Am Acad Dermatol (February) 2008; AB125. P2640.

295.    Revicki D, Menter A, Saurat J, Kaul M.  Association between clinical response and health-related quality of life outcomes for patients with moderate to severe psoriasis.  J Am Acad Dermatol (February) 2008; AB128, P2651.

296.    Shah S, Arthur A, Stevens S, Yang Y-C.  A retrospective study to investigate ethnic variations in the treatment of psoriasis with etanercept.  J Am Acad Dermatol (February) 2008; AB128, P2652.

297.    Moya S E M, Aragones L T.  Treatment with 0.1% tacrolimus cream for mild to moderate plaque psoriasis.  J Am Acad Dermatol (February) 2008; AB129, P2655.

298.    Rich P.  Efficacy and safety of efalizumab for nail psoriasis:  Results of an open-label, multicentre study.  J Am Acad Dermatol (February) 2008; AB130, P2658.

299.    Strengel F M, Chouela E, Takahashi M D F, Amaya M. Efficacy of efalizumab for the treatment of moderate to severe plaque psoriasis:  A prospective, 24 week, open-label phase IIIb/IV clinical trial in patients from Latin America.  J Am Acad Dermatol (February) 2008; AB133, P2670.

300.    Gupta A, Bolduc C, Gu Y, Willian M K.  Patients with moderate versus severe psoriasis experience similar magnitudes of improvement in dermatology-specific health-related quality of life with Adalimumab therapy:  Subanalysis of multiple placebo-controlled trials.  J Am Acad Dermatol (February) 2008; AB135, P2678.

301.    Taieb C, Martinsic M A, Bousetta S, Nocera T.  Psoriasis and thermal therapy:  Evaluation of medical service.  J Am Acad Dermatol (February) 2008; AB135, P2679.

DLQI

Further Information

For general queries, technical aspects and permission to use:

E-mail: dermqol@cf.ac.uk

Other contacts:

Mrs Joy Hayes (financial aspects):
HayesJ@cf.ac.uk

Professor Andrew Y Finlay:
FinlayAY@cf.ac.uk

Address:
Department of Dermatology
Cardiff University School of Medicine
Heath Park, Cardiff
CF14 4XN
United Kingdom
Tel: +44 (0)29 2074 2884
Fax: +44 (0)29 2074 4321

FAQs

Quality of Life FAQs

Publications

Key References
Full Reference List